Prasco To Distribute Eli Lilly's Generic Version Of Evista

(RTTNews) - Prasco Laboratories said Tuesday it has signed a marketing and distribution agreement with Eli Lilly and Company (LLY) to market the authorized generic version of Evista in 60 mg strength in the U.S. The healthcare company did not disclose the financial terms of the transaction.

Evista (raloxifene hydrochloride tablets) is an estrogen agonist/antagonist for the treatment of osteoporosis in postmenopausal women, and for reduction of risk of invasive breast cancer in postmenopausal women with osteoporosis and risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.